Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Identification and validation of human proteins that control tau seeding in cell-based and in vivo models

Tau Seeding

The microtubule-associated protein tau is the most commonly misfolded protein in neurodegenerative disorders including Alzheimer’s disease and other related tauopathies. These neurological illnesses are hypothesized to share a common mechanism of disease progression, where pathogenic aggregates or ‘seeds’ of the tau protein function as templates...

Funding Programme
Start Date
End Date
Total Funding
€ 171 461
European Countries Involved

Identifying and deciphering the mechanism of the cellular machinery responsible for disaggregation of intracellular prion-like Tau aggregates

REVERSING TAUOPATHY

Tauopathies are a group of neurodegenerative diseases, the most common of them being Alzheimer’s disease, which are associated with the aggregation of protein Tau in the brain. Despite major research efforts world-wide, the mechanism of Tau aggregation and its pathogenesis giving rise to such neurodegenerative diseases is not yet understood...

Funding Programme
Start Date
End Date
Total Funding
€ 171 461
European Countries Involved

Identifying preclinical Alzheimer´s disease in the community using a panel of biomarkers among individuals with Subjective Memory Complaints

IPACBIS

The dementia epidemic is a growing socio-economical problem in developed countries, including Europe, mainly due to aged population. Alzheimer´s disease (AD), the leading cause of dementia, has currently no prevention or cure. Identifying AD at early stages will likely improve the chances of developing an effective therapy. AD-related changes can...

Funding Programme
Start Date
End Date
Total Funding
€ 158 122
European Countries Involved

Imaging synaptic contributors to dementia

ALZSYN

Alzheimer's disease, the most common cause of dementia in older people, is a devastating condition that is becoming a public health crisis as our population ages. Despite great progress recently in Alzheimer’s disease research, we have no disease modifying drugs and a decade with a 99.6% failure rate of clinical trials attempting to treat the...

Funding Programme
Start Date
End Date
Total Funding
€ 2 000 000
European Countries Involved

Immune checkpoint blockade for fighting Alzheimer’s disease

ImmuneCheckpointsAD

Understanding, and ultimately treating Alzheimer’s disease (AD) is a major need in Western countries. Currently, there is no available treatment to modify the disease. Several pioneering discoveries made by my team, attributing a key role to systemic immunity in brain maintenance and repair, and identifying unique interface between the brain’s...

Funding Programme
Start Date
End Date
Total Funding
€ 2 287 500
European Countries Involved

Immunological mechanisms of post-stroke dysfunction and recovery of neurovascular coupling

VasoRecovery

Ischemic stroke is one of the most common causes of disability and death in the EU. Improvements in treatment and prevention of ischemic stroke have reduced this burden, but consequently, patients living with chronic post-stroke conditions are increasing in number. Addressing this emergent public health problem will require novel rehabilitation...

Funding Programme
Start Date
End Date
Total Funding
€ 162 806
European Countries Involved

Impact of Environmental Tobacco Smoke on Incidence and Outcomes of Dementia.

DEMETS

Environmental Tobacco Smoke (ETS) remains prevalent globally. Its association with dementia is unclear. We propose to investigate impacts of ETS on dementia risk and outcomes, and examine levels and determinants of ETS exposure post dementia. In a case-control study in the UK we will recruit 150 elders aged>=75 years with newly diagnosed dementia...

Funding Programme
Start Date
End Date
Total Funding
€ 195 455
European Countries Involved

implementAtion anD OPeration of the gateway for healTh into BBMRI-ERIC

ADOPT BBMRI-ERIC

BBMRI-ERIC: the Biobanking and BioMolecular resources Research Infrastructure - European Research Infrastructure Consortium, aims to establish, operate and develop a Pan-European distributed research infrastructure in order to facilitate the access to biological resources as well as facilities and to support high quality biomolecular and biomedical...

Funding Programme
Start Date
End Date
Total Funding
€ 4 949 449

In search for endothelial mechanisms of TPO-induced neuroprotection

TONEURENDO

Ageing is recognized as one of the greatest social and economical challenges of the 21century for European societies. With, Vascular Cognitive Impairment (VCI) being one of the leading causes of age-related cognitive impairment and one of the major causes of disability in the elderly. Although, the concept of VCI was introduced in 1993, current...

Funding Programme
Start Date
End Date
Total Funding
€ 146 462
European Countries Involved

IN-CYTES A HIGH-DENSITY MICROELECTRODE ARRAY PLATFORM FOR LARGE-SCALE INTRACELLULAR FUNCTIONAL ASSAYS

In-Cytes

MaxWell Biosystems AG (MxW) is a Swiss public limited company (AG) who developed electrophysiological platforms (hardware-software-bioassays) for basic research and drug testing on nerve cells. MxW’s aim is to develop In-Cytes, a radically innovative electrophysiology platform to assess neural connectivity for preclinical drug discovery for brain...

Funding Programme
Start Date
End Date
Total Funding
€ 135 500
European Countries Involved

INdependent LIving support Functions for the Elderly

IN LIFE

The number of elderly living with cognitive impairment is growing rapidly due to increasing life expectancy. The percentage of those who live alone depends upon the condition (i.e. roughly 30% of those diagnosed with dementia) but the majority would like to live in their own home or with family, provided that it is safe, comfortable, and cost...

Funding Programme
Start Date
End Date
Total Funding
€ 3 761 729
European Countries Involved

INNOVATIVE WATER-SOLUBLE PHYTOMATERIAL INHIBITORs FOR ALZHEIMERs AND PARKINSONs DISEASES PREVENTION

PhytoAPP

Under PhytoAPP project it is expected to build new and enhance existing network of international and inter-sectoral cooperation in the form of joint research and innovation activities between the project Partners with multidisciplinary skills and complementary competences in nanomaterials, physics, engineering, green chemistry, biochemistry and...

Funding Programme
Start Date
End Date
Total Funding
€ 1 021 200
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).